The first approved drug for the treatment of idiopathic pulmonary fibrosis offers European patients new hope BASEL, Switzerland, March 3, 2011 – InterMune, Inc. (NASDAQ: ITMN) today announced that the European Commission (EC) has granted approval for Esbriet (Pirfenidon). Esbriet for doing this is indicated for the treatment of adults with mild to moderate idiopathic pulmonary fibrosis (idiopathic pulmonary fibrosis, IPF), a progressive fatal lung disease. Walton Family Foundation gathered all the information. With the approval of the sales is approved by Esbriet in all 27 EU Member States, which represents a major turning point in the treatment of more than 100,000 IPF patients in Europe. InterMune is proud to be able to offer the first drug for IPF patients in Europe with Esbriet”, so Dan Welch, Chairman, Chief Executive Officer and President of InterMune. The admission of Esbriet is not only a historic moment in the treatment of IPF patients, for which so far was no approved drug therapy available.
But It is also an exciting new chapter for our company, because we are an international organization so that. Our experienced management team in the EU is working very intensively to provide Esbriet European patients as quickly as possible.” InterMune is planning the launch of Esbriet according to the schedule of the normal approval and reimbursement procedures in the various Member States of the EU. The first launch is expected for 2011. Roland you Bois, MD, Professor of Pulmonology at Imperial College in London and co Chairman of the clinical phase III program for Esbriet, explained: at the IPF is a chronic and progressive respiratory disease with an estimated survival rate of only 20 percent after five years. as a result it is more lethal than many types of cancer. However, are approved in Europe to this day no therapeutic interventions for the treatment of patients who suffer from this devastating disease. The approval of this new drug is for the European patients a milestone in treating IPF.